Last Reviewed : 12/24/2020

Myelofibrosis, also known as osteomyelofibrosis, is a rare bone marrow cancer. It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic stem cells in the bone marrow and other sites results infibrosis, or the replacement of the marrow with scar tissue.

The term myelofibrosis alone usually refers to primary myelofibrosis (PMF), also known as chronic idiopathic myelofibrosis(cIMF); the terms idiopathic and primary mean that in these cases the disease is of unknown or spontaneous origin. This is in contrast with myelofibrosis that develops secondary to polycythemia vera or essential thrombocythaemia. Myelofibrosis is a form ofmyeloid metaplasia, which refers to a change in cell type in the blood-forming tissue of the bone marrow, and often the two terms are used synonymously. The terms Agnogenic myeloid metaplasia and myelofibrosis with myeloid metaplasia (MMM) are also used to refer to myelofibrosis.

We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.


Basic information: mayo clinic myelofibrosis definition lekemia foundation primary myelofibrosis medline plus myelofibrosis merck manuals(professional version) primary myelofibrosis cleveland clinic myelofibrosis web md myelofibrosis new york times primary myelofibrosis university of maryland medical center myelofibrosis


Advanced information: medscape primary myelofibrosis patient myelofibrosis primary myelofibrosis oncolink myelofibrosis cancer research uk myelofibrosis radiopedia myelofibrosis myeloproliferative neoplasms myelofibrosis symptom control takes ‘significant’ step forward with ruxolitinib approval ahro guideline summary blood ref myelofibrosis prognosis dipss, iwg-mrt and lille prognostic scores for myelofibrosis


Research: keith l. davis, isabelle côté, james a. kaye, estella mendelson, haitao gao, and julian perez ronco, “real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib,” advances in hematology, vol. 2015, article id 848473, 9 pages, 2015. doi:10.1155/2015/848473 splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of janus kinase 2 inhibitors by jasleen randhawa et al., journal of hematology & oncology20125:43 doi: 10.1186/1756-8722-5-43

malhotra h. janus activated kinase inhibition in myelofibrosis. indian j cancer [serial online] 2012 [cited 2016 jun 29];49:260-5. available from:

dewan u, kumari n, jaiswal a, behari s, jain m. extramedullary hemopoiesis with undiagnosed, early myelofibrosis causing spastic compressive myelopathy: case report and review. indian j orthop [serial online] 2010 [cited 2016 jun 29];44:98-103. available from: ayed a. algarni, mojtaba akhtari, and kai fu, “myelodysplastic syndrome with myelofibrosis transformed to a precursor b-cell acute lymphoblastic leukemia: a case report with review of the literature,” case reports in hematology, vol. 2012, article id 207537, 6 pages, 2012. doi:10.1155/2012/207537 calreticulin mutations in myeloproliferative neoplasms by noa lavi, m.d. rambam maimonides medical journal 2014 october; 5(4): e0035. issn: 2076-9172 pulmonary hypertension diagnosed by echocardiography during idiopathic myelofibrosis. a case report and a brief review of the literature by claudio perrone et al., multidisciplinary respiratory medicine20105:267 doi: 10.1186/2049-6958-5-4-267 clinics vol.68 no.3 são paulo 2013 clinical science:primary myelofibrosis: risk stratification by ipss identifies patients with poor clinical outcome by bruno deltreggia benites et al., a. etienne, b. gruson, d. chatelain, et al., “myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review,” advances in hematology, vol. 2009, article id 179847, 5 pages, 2009. doi:10.1155/2009/179847 ghulam rehman mohyuddin and abdulraheem yacoub, “primary myelofibrosis presenting as extramedullary hematopoiesis in a transplanted liver graft: case report and review of the literature,” case reports in hematology, vol. 2016, article id 9515404, 3 pages, 2016. doi:10.1155/2016/9515404 christophe desterke, christophe martinaud, nadira ruzehaji, and marie-caroline le bousse-kerdilès, “inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis,” mediators of inflammation, vol. 2015, article id 415024, 16 pages, 2015. doi:10.1155/2015/415024


Other helpful resources(support groups): mpn research foundation myelofibrosis


Related videos: what is primary myelofibrosis? what is primary myelofibrosis? myelofibrosis disease overview and treatment options current developments in myelofibrosis treatment understanding myelofibrosis jak2 inhibition in the treatment of myelofibrosis novel agents and combination therapies in myelofibrosis

Please leave your comments:

Related Articles